TY - JOUR
T1 - A Host Transcriptional Signature for Presymptomatic Detection of Infection in Humans Exposed to Influenza H1N1 or H3N2
AU - Woods, Christopher W.
AU - McClain, Micah T.
AU - Chen, Minhua
AU - Zaas, Aimee K.
AU - Nicholson, Bradly P.
AU - Varkey, Jay
AU - Veldman, Timothy
AU - Kingsmore, Stephen F.
AU - Huang, Yongsheng
AU - Lambkin-Williams, Robert
AU - Gilbert, Anthony G.
AU - Hero, Alfred O.
AU - Ramsburg, Elizabeth
AU - Glickman, Seth
AU - Lucas, Joseph E.
AU - Carin, Lawrence
AU - Ginsburg, Geoffrey S.
N1 - Generated from Scopus record by KAUST IRTS on 2021-02-09
PY - 2013/1/9
Y1 - 2013/1/9
N2 - There is great potential for host-based gene expression analysis to impact the early diagnosis of infectious diseases. In particular, the influenza pandemic of 2009 highlighted the challenges and limitations of traditional pathogen-based testing for suspected upper respiratory viral infection. We inoculated human volunteers with either influenza A (A/Brisbane/59/2007 (H1N1) or A/Wisconsin/67/2005 (H3N2)), and assayed the peripheral blood transcriptome every 8 hours for 7 days. Of 41 inoculated volunteers, 18 (44%) developed symptomatic infection. Using unbiased sparse latent factor regression analysis, we generated a gene signature (or factor) for symptomatic influenza capable of detecting 94% of infected cases. This gene signature is detectable as early as 29 hours post-exposure and achieves maximal accuracy on average 43 hours (p = 0.003, H1N1) and 38 hours (p-value = 0.005, H3N2) before peak clinical symptoms. In order to test the relevance of these findings in naturally acquired disease, a composite influenza A signature built from these challenge studies was applied to Emergency Department patients where it discriminates between swine-origin influenza A/H1N1 (2009) infected and non-infected individuals with 92% accuracy. The host genomic response to Influenza infection is robust and may provide the means for detection before typical clinical symptoms are apparent. © 2013 Woods et al.
AB - There is great potential for host-based gene expression analysis to impact the early diagnosis of infectious diseases. In particular, the influenza pandemic of 2009 highlighted the challenges and limitations of traditional pathogen-based testing for suspected upper respiratory viral infection. We inoculated human volunteers with either influenza A (A/Brisbane/59/2007 (H1N1) or A/Wisconsin/67/2005 (H3N2)), and assayed the peripheral blood transcriptome every 8 hours for 7 days. Of 41 inoculated volunteers, 18 (44%) developed symptomatic infection. Using unbiased sparse latent factor regression analysis, we generated a gene signature (or factor) for symptomatic influenza capable of detecting 94% of infected cases. This gene signature is detectable as early as 29 hours post-exposure and achieves maximal accuracy on average 43 hours (p = 0.003, H1N1) and 38 hours (p-value = 0.005, H3N2) before peak clinical symptoms. In order to test the relevance of these findings in naturally acquired disease, a composite influenza A signature built from these challenge studies was applied to Emergency Department patients where it discriminates between swine-origin influenza A/H1N1 (2009) infected and non-infected individuals with 92% accuracy. The host genomic response to Influenza infection is robust and may provide the means for detection before typical clinical symptoms are apparent. © 2013 Woods et al.
UR - https://dx.plos.org/10.1371/journal.pone.0052198
UR - http://www.scopus.com/inward/record.url?scp=84872252677&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0052198
DO - 10.1371/journal.pone.0052198
M3 - Article
SN - 1932-6203
VL - 8
JO - PLoS ONE
JF - PLoS ONE
IS - 1
ER -